Can I Take Resveratrol with Lantus (Insulin Glargine)?

What Is the Interaction Between Resveratrol and Insulin Glargine?

The interaction is primarily pharmacodynamic. Resveratrol activates SIRT1, AMPK, and GLUT4 signaling, all of which improve insulin sensitivity and lower fasting blood glucose independently of any injected insulin. When added to a stable Lantus dose, this extra glucose-lowering effect can push blood sugar below safe thresholds.

A 2020 meta-analysis of 17 randomized controlled trials (N=832) published in Nutrition, Metabolism and Cardiovascular Diseases found that resveratrol supplementation reduced fasting plasma glucose by a mean of 10.2 mg/dL (95% CI: 5.4 to 15.0 mg/dL) compared with placebo in people with type 2 diabetes 1. That degree of additional glucose reduction, layered on top of a calibrated basal insulin dose, is enough to cause symptomatic hypoglycemia in susceptible individuals.

Pharmacodynamic Pathway: How Resveratrol Lowers Glucose

Resveratrol's glucose effects run through at least three molecular pathways:

SIRT1 activation. SIRT1 deacetylates PGC-1alpha, improving mitochondrial function and hepatic insulin sensitivity. A 2013 study in Cell Metabolism linked SIRT1-mediated pathways to a 15% to 30% reduction in hepatic glucose output in rodent models 2.

AMPK phosphorylation. Resveratrol phosphorylates AMPK at Thr172, mimicking the glucose-lowering action of metformin. This effect increases glucose uptake in skeletal muscle without requiring additional insulin signaling 3.

GLUT4 translocation. Several in vitro studies show resveratrol promotes GLUT4 movement to the cell surface, raising peripheral glucose disposal. This action overlaps directly with insulin glargine's primary mechanism of action.

Pharmacokinetic Component: CYP Enzyme Inhibition

Insulin glargine is a peptide degraded by proteases, not by cytochrome P450 enzymes. So CYP inhibition by resveratrol does not directly change Lantus exposure. Still, resveratrol inhibits CYP3A4 and CYP2C9 at concentrations achievable with high-dose supplements (above 500 mg per day), which could affect co-medications such as sulfonylureas or warfarin that a person with diabetes might also be taking 4. If you take a sulfonylurea alongside Lantus, the CYP2C9 inhibition by resveratrol becomes a separate and clinically meaningful concern.

What Does the Clinical Evidence Actually Show?

Human trials on resveratrol in diabetes are small and heterogeneous, but a consistent signal toward glucose lowering has emerged.

Key Randomized Controlled Trials

Bhatt et al. (2012). A 4-week RCT (N=62) published in Nutrition Research tested resveratrol 250 mg twice daily in patients with type 2 diabetes on oral agents. Mean fasting glucose dropped by 26.5 mg/dL versus 1.5 mg/dL in the placebo arm (P<0.001) 5. No patients in this trial used insulin, so direct extrapolation to Lantus users requires caution, but the magnitude of glucose reduction is noteworthy.

Movahed et al. (2013). A 45-day trial (N=66) published in Journal of Research in Medical Sciences examined resveratrol 1,000 mg per day in type 2 diabetes and reported HbA1c reductions of 0.45% and fasting glucose reductions of approximately 22 mg/dL 6. Again, insulin users were excluded, but the direction is consistent.

Timmers et al. (2011). Published in Cell, this 30-day study (N=11) in healthy obese men using resveratrol 150 mg per day found improved insulin sensitivity by HOMA-IR without clinical hypoglycemia, though all subjects had normal-range fasting glucose at baseline 7.

What the ADA Guidelines Say About Supplements

The American Diabetes Association (ADA) 2024 Standards of Care in Diabetes state: "There is no clear evidence of benefit from vitamin or mineral supplementation in people with diabetes who do not have underlying deficiencies, and routine supplementation is not recommended" 8. The ADA does not specifically prohibit resveratrol, but the guidance reflects the general evidentiary gap.

Who Is at Highest Risk for Hypoglycemia From This Combination?

Not every person taking Lantus carries the same hypoglycemia risk when adding resveratrol. Risk stratification matters.

High-Risk Patients

Patients who fall into any of the following categories should discuss the combination with a physician before trying resveratrol:

• Current HbA1c <7.0%, indicating already tight glycemic control
• History of severe hypoglycemia (defined as an event requiring third-party assistance) within the past 12 months
• Hypoglycemia unawareness, documented or suspected
• Renal impairment (eGFR <45 mL/min/1.73m2), which prolongs insulin action and slows glucose recovery
• Concurrent use of other glucose-lowering agents (metformin, GLP-1 receptor agonists, SGLT-2 inhibitors, sulfonylureas)

Moderate-Risk Patients

Patients with stable, well-controlled type 2 diabetes on Lantus alone, with HbA1c between 7.0% and 8.5%, and no history of unawareness may be reasonable candidates for a monitored trial at lower resveratrol doses (100 mg to 250 mg per day), provided blood glucose is checked more frequently during the first two to four weeks.

Lower-Risk Context

Type 1 diabetes patients on Lantus are not in a lower-risk category. Type 1 patients lack any endogenous insulin buffering, so additive glucose lowering from resveratrol carries a steeper hypoglycemia trajectory. An endocrinologist should be involved before any supplementation in this group.

Does Timing or Dose Separation Reduce the Risk?

Separating the timing of resveratrol from a Lantus injection does not meaningfully reduce pharmacodynamic overlap. Insulin glargine provides a flat, 24-hour peakless basal profile. Resveratrol's SIRT1 and AMPK effects persist for 12 to 24 hours post-dose in animal models 3. There is no discrete pharmacokinetic interaction window to exploit.

Dose separation is a relevant strategy when two drugs interact via absorption competition or shared enzyme metabolism. Because this interaction is a shared physiologic outcome (lower blood glucose), the only effective mitigation is monitoring and potential Lantus dose adjustment, not scheduling.

Lower resveratrol doses carry proportionally lower risk. Trials using 150 mg per day showed smaller glycemic effects than trials at 500 mg to 1,000 mg per day. If your clinician approves the combination, starting at 100 mg to 150 mg per day is a more conservative entry point than a "longevity dose" of 500 mg or higher.

How Should Blood Glucose Be Monitored If Taking Both?

Structured self-monitoring is the cornerstone of safe combination use. A practical monitoring protocol for someone adding resveratrol to a stable Lantus dose would include:

Weeks 1 Through 2

Check fasting glucose every morning and a bedtime glucose reading nightly. Log all values. The goal is to identify a downward trend before it reaches hypoglycemic thresholds (<70 mg/dL by the ADA definition) 9.

Weeks 3 Through 4

If fasting glucose has dropped more than 15 to 20 mg/dL from baseline or is consistently below 100 mg/dL before breakfast, contact your prescriber. A 10% to 15% Lantus dose reduction is a common clinical response to a confirmed sensitizing interaction.

Ongoing

If the combination is tolerated after 4 weeks with no hypoglycemia, routine monitoring can return to the patient's usual frequency. Annual HbA1c remains the standard long-term marker, supplemented by time-in-range data for continuous glucose monitor users.

The Endocrine Society's clinical practice guideline on hypoglycemia in adults with diabetes specifies that a blood glucose <54 mg/dL constitutes a "clinically significant" hypoglycemia event requiring immediate response and medication review 10.

Resveratrol's Other Claimed Effects Relevant to People with Diabetes

Resveratrol is sold for reasons beyond blood sugar. Understanding those claims helps patients weigh the risk-benefit balance more accurately.

Cardiovascular Claims

Resveratrol's reputation as a cardioprotective compound derives largely from the "French Paradox" hypothesis and early preclinical data. A 2018 Cochrane-style systematic review of resveratrol and cardiovascular risk markers found modest reductions in systolic blood pressure (mean -2.6 mmHg) and LDL cholesterol, but the authors concluded the evidence base was insufficient to recommend supplementation for cardiovascular endpoints 11. People with diabetes already carry elevated cardiovascular risk; adding a supplement with uncertain cardiac benefit and a concrete hypoglycemia risk is a trade-off worth scrutinizing carefully.

Estrogenic Activity

Resveratrol acts as a selective estrogen receptor modulator (SERM) with weak affinity for ERalpha and ERbeta 12. This estrogenic activity is typically discussed in the context of hormone-sensitive cancers or interactions with hormone replacement therapy. For most men and postmenopausal women on Lantus, this property is not an immediate concern, but it is a consideration for premenopausal women with estrogen-sensitive conditions.

Anti-Inflammatory Effects

Several trials show resveratrol reduces C-reactive protein and TNF-alpha, which are elevated in type 2 diabetes. A 2015 meta-analysis (N=388 across 9 RCTs) reported a significant reduction in CRP of 0.79 mg/L (P<0.001) with resveratrol supplementation 13. Whether this anti-inflammatory effect translates to clinical diabetes outcomes remains unproven.

What to Tell Your Prescriber Before Starting Resveratrol

Bring the following information to your appointment or telehealth consultation:

• The exact resveratrol product, dose in milligrams, and intended frequency
• Your current Lantus dose in units and injection timing
• Any other glucose-lowering medications or supplements you take
• Your most recent HbA1c value and fasting glucose averages
• Any history of hypoglycemia, including mild events

The FDA does not regulate supplements with the same rigor applied to prescription drugs 14. Product quality varies. If your prescriber approves resveratrol, choosing a product with third-party testing (NSF International or USP verification) reduces the risk of mislabeled doses that could amplify the glucose-lowering effect unexpectedly.

Resveratrol Dose Reference Table

| Resveratrol Daily Dose | Glycemic Effect (Human Trials) | Relative Hypoglycemia Risk on Lantus | |---|---|---| | 100 to 150 mg | Minimal; mixed evidence | Low to moderate | | 250 to 500 mg | Fasting glucose -10 to -26 mg/dL | Moderate | | 1,000 mg | Fasting glucose -22 mg/dL; HbA1c -0.45% | High |

Dose estimates are drawn from the trials cited above 5 6 7. All participants in those trials were on oral agents, not insulin. The risk column is a clinical estimate, not a validated scoring tool.

Summary of Clinical Decision Points

For a person currently stable on insulin glargine who wants to try resveratrol, the clinical sequence is:

1. Confirm baseline HbA1c and fasting glucose before starting.
2. Get explicit prescriber approval, not just a pharmacist check.
3. Start at 150 mg per day or below if approved.
4. Increase fasting and bedtime glucose monitoring for the first 30 days.
5. If fasting glucose drops more than 15 mg/dL below personal target, pause resveratrol and call your care team that day.
6. Avoid doses above 500 mg per day without a formal medication review.

The ADA's 2024 Standards of Care recommend that "all patients with diabetes who use insulin should have access to a glucagon rescue kit" and that providers counsel on hypoglycemia recognition and treatment at every visit 8. Having glucagon (nasal powder or autoinjector) on hand is advisable any time a new glucose-lowering exposure is introduced.